Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13-14
pubmed:dateCreated
2001-2-22
pubmed:abstractText
Effects of intranasal administration of cholera toxin (CT) [or Escherichia coli heat-labile enterotoxin (LT)] B subunits supplemented with a trace amount of the holotoxin, CTB* or LTB*, on the brain were examined in BALB/c mice by comparing with those of the intracerebral injection. Intracerebral injection of CTB* at doses more than 10 microg/mouse caused significant body weight loss and dose-dependent death within 7 days, with localization of conjugates of horseradish peroxidase with CTB (HRP-CTB) in the ventricular system and in the perineural space of olfactory nerves of the nasal mucosa 3 h after injection. Intracerebral injection of CTB* at doses less than 3 microg/mouse (or LTB* at doses less than 22.7 microg/mouse) did not cause any significant body weight loss for 7 days, with localization of HRP-CTB in the brain but not in the nasal mucosa. On the other hand, intranasal administration of 10 microg of CTB* caused localization of HRP-CTB in the nasal mucosa but not in the brain 3 h after administration and caused body weight loss even after 30 administrations. Neither any histological changes of brain tissues nor marked changes in serum biochemical parameters were found in mice after the 30 administrations of CTB* or LTB*. These results suggest that 0.1 microg of CTB* or LTB*, which is known to be close to the minimal effective dose as an adjuvant for nasal influenza vaccine in mice and corresponds to 100 microg per person, can be used as a safe nasal adjuvant without adversely affecting the brain.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
8
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1652-60
pubmed:dateRevised
2003-11-14
pubmed:meshHeading
pubmed-meshheading:11166888-Adjuvants, Immunologic, pubmed-meshheading:11166888-Administration, Intranasal, pubmed-meshheading:11166888-Animals, pubmed-meshheading:11166888-Blood Proteins, pubmed-meshheading:11166888-Body Weight, pubmed-meshheading:11166888-Brain, pubmed-meshheading:11166888-Cholera Toxin, pubmed-meshheading:11166888-Dose-Response Relationship, Drug, pubmed-meshheading:11166888-Enterotoxins, pubmed-meshheading:11166888-Escherichia coli, pubmed-meshheading:11166888-Female, pubmed-meshheading:11166888-Glycosides, pubmed-meshheading:11166888-Horseradish Peroxidase, pubmed-meshheading:11166888-Immunity, Mucosal, pubmed-meshheading:11166888-Injections, Intraventricular, pubmed-meshheading:11166888-Mice, pubmed-meshheading:11166888-Mice, Inbred BALB C, pubmed-meshheading:11166888-Nasal Mucosa, pubmed-meshheading:11166888-Olfactory Nerve, pubmed-meshheading:11166888-Protein Subunits, pubmed-meshheading:11166888-Survival Rate, pubmed-meshheading:11166888-Triterpenes
pubmed:year
2001
pubmed:articleTitle
Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.
pubmed:affiliation
Department of Pathology, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, 162-8640, Tokyo, Japan.
pubmed:publicationType
Journal Article